证券代码：688710 证券简称：益诺思 公告编号：2026-002 上海益诺思生物技术股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海益诺思生物技术股份有限公司（以下简称"公司"）股票于 2026 年 1 月 7 日、2026 年 1 月 8 日、2026 年 1 月 9 日连续三个交易日内收盘价格涨幅偏 离值累计超过 30%，根据《上海证券交易所交易规则》《上海证券交易所科创板 股票异常交易实时监控细则》有关规定，属于股票交易异常波动的情形。 经公司自查，并书面发函公司控股股东、实际控制人，截至本公告披露日， 公司、控股股东及实际控制人不存在关于公司应披露而未披露的重大事项。公司 目前生产经营正常，生产经营未发生重大变化。 一、股票交易异常波动的具体情况 截至 2026 年 1 月 9 日上海证券交易所交易收盘，本公司股票交易连续三个 交易日收盘价格涨幅偏离值累计超过 30%，根据《上海证券交易所交易规则》《上 海证券交易所科创板股票异常交易实时监控细则》的有关规定，属于股 ...

Core Viewpoint - The company announced that its stock price experienced an abnormal fluctuation, with a cumulative increase of over 30% during the trading days from January 7 to January 9, 2026 [1] Company Status - As of the announcement date, the company, its controlling shareholder, and actual controller confirmed that there are no undisclosed significant matters [1] - The company's production and operations are normal, with no major changes reported [1] Market Activity - The company did not identify any media reports or market rumors that could influence its stock price [1] - During the period of abnormal fluctuation, the company's directors, supervisors, and senior executives did not engage in buying or selling the company's stock [1] Investor Advisory - The company reminded investors to refer to official announcements for accurate information and to invest rationally [1]

Market Performance - The A-share market showed significant strength with the Shanghai Composite Index rising by 0.92%, surpassing 4100 points, marking a new high in over 10 years [1] - For the week, the Shanghai Composite Index increased by 3.82%, the Shenzhen Component Index by 4.4%, and the ChiNext Index by 3.89% [1] Trading Volume - The total market turnover exceeded 3.15 trillion yuan, an increase of 326.1 billion yuan from the previous trading day, marking the sixth occurrence in history where turnover surpassed 3 trillion yuan [3] - Over 3900 stocks in the market experienced gains [3] AI Sector - The AI application sector saw a collective surge, with concepts like Xiaohongshu leading the gains, followed by Sora and Kuaishou [3][7] - The AI application sector is expected to enter a "golden year" in 2026, driven by technological maturity, supportive policies, and market demand [10][11] Notable Stocks - Zhite New Materials became the first stock to double in 2026, with a price increase of over 148% from January 5 to January 9, achieving five consecutive "20CM" limit-ups [3][4] - The stock is associated with AI-driven scientific research, new materials, robotics, and quantum technology [4][5] Innovation Drug Sector - The innovative drug sector experienced a strong rally, with companies like Weikang Pharmaceutical and Qianyan Bio hitting the "20CM" limit-up [13] - The National Medical Products Administration is optimizing the approval process for urgently needed foreign drugs, which is expected to support the innovative drug sector's growth [16][17]

格隆汇1月8日丨益诺思(688710.SH)公布，公司于2026年1月8日收到张江生药基地出具的书面告知函。 截至2026年1月7日，张江生药基地通过集中竞价方式减持公司140.98万股股份，占公司总股本的 1.00%。 ...

证券代码：688710 证券简称：益诺思 公告编号：2026-001 上海益诺思生物技术股份有限公司 股东权益变动触及 1%刻度暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，上海张江生物医药基地开发有限公司（以下简称"张 江生药基地"）持有上海益诺思生物技术股份有限公司（以下简称"公司"） 11,020,753 股，占公司总股本的 7.82%。上述股份均为公司首次公开发行前取得 股份，且已于 2025 年 9 月 3 日解除限售并上市流通。 减持计划的实施结果情况 2025 年 11 月 29 日，公司在上海证券交易所网站披露了《股东减持股份计划 公告》，张江生药基地计划自 2025 年 12 月 22 日至 2026 年 3 月 20 日期间通过集 中竞价交易方式减持其所持有的公司股份数量不超过 1,409,796 股股份，占公司 总股本的比例不超过 1.00%。 公司于 2026 年 1 月 8 日收到张江生药基地出具的书面告知 ...

Core Viewpoint - The announcement indicates a reduction in shareholding by Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. in the company, which does not affect the control structure or governance of the company [1] Group 1: Shareholding Changes - Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. reduced its shareholding from 11,020,753 shares to 9,610,957 shares [1] - The percentage of total share capital held by Zhangjiang decreased from 7.82% to 6.82% [1] - The reduction involved a sale of 1,409,796 shares through a centralized bidding transaction, and the plan has been fully implemented [1] Group 2: Impact on Company Structure - The shareholding change does not trigger a mandatory tender offer [1] - There will be no change in the company's controlling shareholder or actual controller [1] - The governance structure and ongoing operations of the company will not be significantly impacted [1]

格隆汇1月8日丨益诺思(688710.SH)公布，公司于2026年1月8日收到张江生药基地出具的书面告知函。 截至2026年1月7日，张江生药基地通过集中竞价方式减持公司140.98万股股份，占公司总股本的 1.00%。 ...

Summary of Key Points Core Viewpoint - The shareholder Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. has completed a share reduction plan, selling 1.4098 million shares of Yinos, which represents 1.00% of the total share capital, at a price range of 43.55 to 55.31 yuan per share, totaling 66.9177 million yuan [1]. Group 1 - The share reduction occurred between December 22, 2025, and January 7, 2026 [1]. - After the reduction, the shareholder holds 9.611 million shares, which is 6.82% of the total shares, down from 11.0208 million shares, or 7.82% prior to the reduction [1]. - This change in equity ownership triggered a change that touches the 1% integer multiple, indicating a significant adjustment in the shareholder's stake [1].

Group 1 - The core point of the article highlights the stock performance of Yinos, which increased by 5.19% to reach a price of 58.18 CNY per share, with a trading volume of 181 million CNY and a turnover rate of 3.57%, resulting in a total market capitalization of 8.202 billion CNY [1] - Yinos is a biotechnology company based in the China (Shanghai) Free Trade Zone, established on May 12, 2010, and listed on September 3, 2024. The company primarily provides non-clinical research services in the biopharmaceutical sector, with 96.31% of its revenue coming from non-clinical services, 3.42% from clinical services, and 0.27% from other sources [1] Group 2 - Among the top ten circulating shareholders of Yinos, a fund under Huatai-PineBridge is noted, specifically the Huatai-PineBridge Healthcare Mixed Fund (470006), which entered the top ten shareholders in the third quarter with 1.1215 million shares, accounting for 1.24% of circulating shares. The estimated floating profit for today is approximately 3.2188 million CNY [2] - The Huatai-PineBridge Healthcare Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.486 billion CNY. Year-to-date returns are 6.72%, ranking 749 out of 8825 in its category, while the one-year return is 36.03%, ranking 3440 out of 8084. Since its inception, the fund has achieved a return of 162.46% [2] - The fund manager of Huatai-PineBridge Healthcare Mixed Fund is Zheng Lei, who has a cumulative tenure of 11 years and 26 days. The total asset scale under his management is 8.093 billion CNY, with the best fund return during his tenure being 53.42% and the worst being -35.19% [2]

Core Insights - The semiconductor ETF Tianhong (159310) has achieved three consecutive days of gains, with a trading volume of 24.21 million yuan, reflecting a strong performance of the underlying index, the CSI Semiconductor Industry Index (H30007), which rose by 1.88% [1] - The Tianhong Science and Technology Innovation Index ETF (589860) also recorded three consecutive days of gains, with a trading volume of 35.92 million yuan, and the underlying index, the SSE Science and Technology Innovation Board Composite Index (000680), increased by 1.53% [1][2] - Samsung Electronics reported a remarkable 208% increase in fourth-quarter profit, driven by a surge in demand for AI servers, which significantly boosted memory chip prices [5] - Eight government departments issued a document to promote the development of intelligent chips, emphasizing the need for advancements in key technologies such as high-end training chips and AI servers [6] Group 1: ETF Performance - The semiconductor ETF Tianhong (159310) has seen a scale increase of 32.55 million yuan over the past two weeks, indicating significant growth [1] - The Tianhong Science and Technology Innovation Index ETF (589860) reached a new high of 313 million yuan, marking its best performance in the last month [2] - The underlying indices for both ETFs reflect strong market activity, with notable gains in constituent stocks such as Changchuan Technology (300604) and Yinuosi (688710) [1][2] Group 2: Market Trends - The DRAM market is experiencing an upward cycle, with a projected increase of 55-60% in contract prices for general DRAM in Q1 2026, driven by supply constraints due to the shift of production to meet AI server demands [6] - The increase in memory chip prices is expected to significantly improve the profitability of domestic storage leaders, as noted by Shengan Securities [6] - The government's focus on enhancing AI computing power and supporting intelligent chip development is likely to create new investment opportunities in the technology sector [6]